You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The new plant will serve as the company's hub for launching multiplexed molecular diagnostic kits for tuberculosis and other infectious disease.
The firm plans to make the molecular testing system accessible to low-income countries, in part by reducing costs using reel-to-reel manufacturing.
TSG is a wholly owned subsidiary of Ascendis Medical and supplies diagnostic laboratory equipment and consumables to pathology laboratories.
In PLOS this week: mutation linked to progressive ataxia in Charolais cattle, microRNA expression levels linked to colorectal cancer, and more.
In addition, Qiagen has partnered with Japan's SRL for companion diagnostic development, and its CareHPV test was added to the WHO list of prequalified IVDs.
The firm will manufacture its Logix Smart mycobacteria tuberculosis assay at its ISO-certified facility in Utah but will not seek FDA approval at this time, it said.
The portable, battery-operated system will be an interim solution for decentralized testing in places where power may be unreliable.
The 20-gene assay, which BioMérieux will develop on the BioFire FilmArray platform, distinguishes active TB from latent TB, viral, and bacterial infections.
At ASM Microbe, the University of Wisconsin's Caitlin Pepperell described her work putting Mycobacterium tuberculosis genomics into a historical context.
Using a protocol developed at the University of Oxford, the researchers hope that nanopore sequencing can aid diagnosis and drug resistance profiling in remote areas.
Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.
The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.
Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.
This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.